Host erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New Guinea by Fowkes, FJI et al.
Malaria Journal Bi.Medcen a 
Open Access Research 
Host erythrocyte polymorphisms and exposure to Plasmodium 
falciparum in Papua New Guinea 
Freya JI Fowkes^1,2, Pascal Miction^1,7, Lynn Pilling1, Ruth M Ripley4, 
Livingstone Tavul3, Heather J Imrie1, Caira M Woods2, Charles S Mgone5,9, 
Adrian JF Luty6,8 and Karen P Day*1,2 
Address: 'The Peter Medawar Building for Pathogen Research, Department of Zoology, University of Oxford, UK, 2Department of Medical 
Parasitology, New York University School of Medicine, New York, USA, 3Papua New Guinea Institute of Medical Research, Madang, Papua New 
Guinea, 4Department of Statistics, University of Oxford, UK, 5African Malaria Network Trust, Dar es Salaam, Tanzania, 6Department of 
Parasitology, Institute for Tropical Medicine, University of Tubingen, Tubingen, Germany, 7PNG Institute of Medical Research, Madang, Papua 
New Guinea, 8Medical Parasitology, MMB-NCMLS, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands and 9European 
Developing Countries Clinical Trials Partnership, Tygerberg, Cape Town, South Africa 
Email: Freya JI Fowkes - fowkes@wehi.edu.au; Pascal Michon - pmichon@datec.net.pg; Lynn Pilling - lynnpilling@hotmail.com; 
Ruth M Ripley - ruth@stats.ox.ac.uk; Livingstone Tavul - ltavul@pngimr.org.pg; Heather J Imrie - h.imrie@ntlworld.com; 
Caira M Woods - cmw364@med.nyu.edu; Charles S Mgone - mgone@edctp.org; Adrian JF Luty - a.luty@mmb.umcn.nl; 
Karen P Day* - karen.day@med.nyu.edu 
* Corresponding author tEqual contributors 
Published: 3 January 2008 Received: 19 April 2007 
Malaria Journal 2008, 7:1 doi:10.1186/1475-2875-7-1 Accepted: 3 January 2008 
This article is available from: http://www.malariajournal.eom/content/7/1/1 
© 2008 Fowkes et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.Org/licenses/by/2.0). 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Abstract 
Background: The protection afforded by human erythrocyte polymorphisms against the malaria 
parasite, Plasmodium falciparum, has been proposed to be due to reduced ability of the parasite to 
invade or develop in erythrocytes. If this were the case, variable levels of parasitaemia and rates of 
seroconversion to infected-erythrocyte variant surface antigens (VSA) should be seen in different 
host genotypes. 
Methods: To test this hypothesis, P. falciparum parasitaemia and anti-VSA antibody levels were 
measured in a cohort of 555 asymptomatic children from an area of intense malaria transmission 
in Papua New Guinea. Linear mixed models were used to investigate the effect of a+-thalassaemia, 
complement receptor-1 and south-east Asian ovalocytosis, as well as glucose-6-phosphate 
dehydrogenase deficiency and ABO blood group on parasitaemia and age-specific seroconversion 
to VSA. 
Results: No host polymorphism showed a significant association with both parasite prevalence/ 
density and age-specific seroconversion to VSA. 
Conclusion: Host erythrocyte polymorphisms commonly found in Papua New Guinea do not 
effect exposure to blood stage P. falciparum infection. This contrasts with data for sickle cell trait 
and highlights that the above-mentioned polymorphisms may confer protection against malaria via 
distinct mechanisms. 
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Background 
Human erythrocyte polymorphisms have long been 
thought to play a role in resistance to malaria. High fre-
quencies of host erythrocyte polymorphisms such as a+-
thalassaemia, haemoglobin (Hb) S, Hb C, Hb E, comple-
ment receptor-1 (CR1) deficiency, glucose-6-phosphate 
dehydrogenase (G6PD) deficiency and south-east Asian 
ovalocytosis (SAO) are found in malaria endemic areas. 
Case-control studies have demonstrated that these poly-
morphisms reduce the risk of severe falciparum malaria 
rather than mild malaria [1-22]. Experimentally, research 
has focused on examining the interactions between the 
parasite and the erythrocyte to try to understand possible 
mechanisms of protection of these polymorphisms. In 
vitro experiments have suggested reduced ability of Plas-
modium falciparum to invade or sustain growth in abnor-
mal erythrocytes [23]. Enhanced clearance of infected 
erythrocytes by phagocytosis, and increased enhanced 
susceptibility of P. falciparum-infected abnormal erythro-
cytes to oxidative stress, have also been proposed [24-28]. 
It has also been hypothesized that a+-thalassaemia, CR1 
deficiency and blood group O may protect via reduced 
rosetting [5,21,29-32], the phenomenon whereby non-
parasitized erythrocytes bind to parasitized erythrocytes. 
It is well documented that individuals with sickle cell trait 
(HbAS) have lower parasite densities compared to HbAA 
individuals in asymptomatic, mild and severe malaria 
[18-20,33-44]. This, together with the observation that 
the time to reappearance of P. falciparum is lower in HbAS 
individuals after drug treatment [39], provides compel-
ling evidence for a direct interaction of the parasite with 
the HbS containing erythrocytes or of improved immu-
nity controlling the level of parasitaemia in those with 
sickle cell trait. However, data on other erythrocyte poly-
morphisms is less clear cut. Clinical studies have rarely 
demonstrated differences in parasite density among geno-
types in symptomatic malaria. Epidemiological studies in 
asymptomatic individuals are inconsistent. Cross-sec-
tional studies have shown that a+-thalassaemia [45,46], 
SAO [47,48], G6PD [49-53] and ABO polymorphisms 
(no studies have examined CR1) have reduced parasite 
rates/densities while other studies provide no evidence of 
an effect of these polymorphisms on parasite densities 
[4,11,54-65]. Data from a single time point may not accu-
rately represent exposure to infection and therefore results 
of these studies are hard to interpret. 
There are two possible ways to measure exposure to 
malaria blood stage infection: 1) by comparing parasite 
prevalence/density and, 2) by comparing age-specific 
antibody seroconversion to major blood stage antigens 
among host genotypes. Seroconversion to P. falciparum-
infected erythrocyte variant surface antigens (VSA), which 
include P. falciparum erythrocyte membrane protein-1 
(PfEMP-1) and rifins, has been shown to be dependent on 
the intensity of transmission [66]. Antibody levels in 
endemic areas reflect the level of IgG seroconversion to P. 
falciparum-infected erythrocyte VSA [67]. Furthermore, a 
study in Tanzania showed that insecticide-treated bednets 
limited the repertoire of recognized VSA and reduced anti-
body levels [68]. Seroconversion can also be considered as 
a marker for the level of cumulative exposure to the para-
site as it increases with age [69]. The more exposure to P. 
falciparum children receive in malaria-endemic areas, the 
younger children wil l seroconvert to VSA. 
If human erythrocyte polymorphisms were to hamper 
invasion and/or growth of the parasite or enhance the 
antibody-dependent control of malarial infection, this 
should manifest as differences in both mean parasite den-
sities and patterns of age-specific seroconversion to VSA. 
The frequency of the host polymorphisms a+-thalassae-
mia, CR1, ABO blood group, SAO and G6PD deficiency 
were determined in a group of children from Papua New 
Guinea (PNG). Parasitological criteria and levels of anti-
VSA antibodies were measured in these children in two 
consecutive surveys, one year apart. The relationship 
between these genetic polymorphisms, parasite preva-
lence/density and age-specific antibody seroconversion to 
VSA was investigated in a malaria endemic region of PNG. 
Methods 
Study design and data collection 
Details of study design and data collection have been 
reported previously [54]. Briefly, a serial cross-sectional 
survey was conducted in asymptomatic children living in 
villages of the Amele region, Madang Province, PNG, 
where intense year-round malaria transmission occurs 
[70]. The study took place from November to December 
of 1999 and 2000 in 566 children aged 1-17 years. A 
serial study design would ensure that any associations 
observed with host genotype would be less likely to have 
occurred by chance. Blood samples were collected using 
Vacutainer® tubes (Becton Dickinson, UK) and EDTA as 
anti-coagulant. A small aliquot of whole blood was blot-
ted onto Isocode® Stix (Schleicher & Schuell GmbH, Das-
sel, Germany) following the manufacturer's instructions, 
for further human genetic analyses. The remaining blood 
was centrifuged and separated into plasma (stored at -
80 °C), buffy coat and erythrocyte pellet, both stored in 
guanidine hydrochloride at 4 °C. 555 paired samples were 
available for antibody determination. 
DNA polymorphism analysis 
a+-Thalassaemia genotype was determined by polymerase 
chain reaction [54]. SAO genotyping was conducted as 
described earlier [71] using human D N A from Isocode® 
Stix. G6PD deficiency was evaluated qualitatively (Sigma 
Diagnostics visual colourimetric assay) and ABO blood 
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groups were determined using anti-A and anti-B antibod-
ies from a kit (BIOSCOT, Edinburgh, Scotland). CR1 gen-
otype was determined by polymerase chain reaction and 
restriction fragment length polymorphism digest with 
Hindlll as previously described with modifications [5,72]. 
Parasites 
P. falciparum isolate P N G / M 12, was collected from a child 
presenting with acute symptomatic malaria at an aid post 
in Madang, during a longitudinal cohort study from 
1990/91 [73]. Erythrocytes were washed three times after 
buffy coat depletion in RPMI 1640 media buffered with 
25 m M 4-(2-hydroxyethyl)-l-piperazineethanesulfonic 
acid (HEPES) and supplemented with 25 m M sodium 
bicarbonate, 2 m M L-glutamine, 300 m M hypoxanthine 
and 10 ug/ml gentamicin (Gibco, UK) (RPMI-HEPES), 
and cryopreserved in liquid nitrogen for adaptation in 
Oxford. Parasites were cultured in vitro using the method 
of Trager and Jensen [74] with modifications [75]. Cells 
were grown in RPMI/HEPES supplemented with 10% AB 
serum (from donors residing in a non-malarious area), in 
an atmosphere of 5% C 0 2 , 2% 0 2 , and 93% N 2 , sub-cul-
tured into O positive erythrocytes (Oxford Blood Transfu-
sion Service, UK) and stabilates frozen down. Adaptation 
and maintenance of PfEMP-1 expressing lines were made 
following a previously published method [67]. 
Surface Immunofluorescence Assay (SIFA) 
Detection of antibodies bound to the surface of infected 
erythrocytes (IE) have previously been described [67]. 
Briefly, trophozoites were synchronized and enriched by 
Plasmagel® (Laboratoire Roger Bellon, France) flota-
tion [76]. After washing 2x in RPMI and lx with human 
tonicity phosphate-buffered saline (HTPBS)/1% BSA 
(Sigma, UK), trophozoite-IE were adjusted to 10 - 15% 
parasitaemia. Fifty u.1 of 1/50 dilution of plasma was 
added to 5 u.1 packed cell volume of IE and incubated for 
30 mins at RT. All washes between each step were done 3x 
with HTPBS/1% Bovine serum albumin (BSA). The next 
antibody layer was a rabbit anti-human IgG (Dako, UK) 
(1/100 dilution). The final antibody layer was a 1/100 
dilution of FITC-coupled swine anti-rabbit IgG (Dako, 
UK) containing 50 ug/ml ethidium bromide. Cells were 
fixed for 1 h with 0.5% paraformaldehyde diluted in 
HTPBS/1% BSA, then washed lx and resuspended with 
HTPBS. Samples were read on a FACSCalibur™ flow 
cytometer (Becton Dickinson, UK): 1000 IE were counted 
using the program CELLQUEST™ 3.3 (Becton Dickinson, 
UK) for Macintosh. A hyper immune plasma (HIP) pool 
from 10 adult residents from Madang and normal human 
serum (NHS) from three non malaria-exposed Europeans 
(Oxford Blood Transfusion Service, UK) were used as pos-
itive and negative controls, respectively, as previously 
described [67]. The percentage of IE staining positive for 
human plasma was calculated relative to the response to 
HIP and NHS as described earlier [67]. 
Statistical analysis 
Due to the repeated measures study design, appropriate 
statistical tests were chosen to analyze paired data. The 
association of host polymorphisms and P. falciparum pres-
ence in no surveys, one survey and two surveys was 
assessed by ordinal regression with adjustments for age. 
Differences in frequency of positive slides were assessed 
using x2 tests for each study year. Linear mixed models 
were used to examine the variation of parasite density 
among host genotypes with adjustments for age. Linear 
mixed models were also used to investigate the effect of 
age, parasite density and genotype on antibody levels: the 
two values were treated as a repeated measure with a het-
erogeneous compound symmetry covariance structure. 
Since the antibody levels showed considerable hetero-
scedasticity, they were transformed before analysis, using 
the transformation log (antibody + 2.5). The P. falciparum 
counts were transformed by log(P. falciparum + 1) to 
reduce skewness while leaving the zero values unchanged. 
The models examined the effect of P. falciparum (loga-
rithm of density), age (continuous), and either a+-thalas-
saemia genotype, CR1 genotype, ABO blood group (four 
categories [A, B, AB, O] and two categories [O and non 
O]), SAO genotype or G6PD phenotype (three categories 
[normal, intermediate, deficient] and two categories [nor-
mal, abnormal]). Interactions between host erythrocyte 
polymorphisms were also examined but some subgroups 
obtained were too small for reliable analysis. An interac-
tion between sex and G6PD deficiency was also examined 
as G6PD deficiency is an X-linked disorder [77]. CR1 
expression has been shown to be associated with a+-tha-
lassaemia genotype [5], therefore adjustments were made 
for the respective polymorphism in ordinal regression and 
mixed linear analysis. Addition of each polymorphism in 
each analysis did not alter the final result so no adjust-
ments were made in the final models. The models were 
developed using R 1.8.1 [78] and SPSS (version 12.0) and 
variables with p-values < .05 were considered significant. 
Informed consent was obtained from subjects and their 
parents or guardians. The project received ethical approval 
from the P N G Medical Research Advisory Committee and 
Institutional Review Board of the New York University 
School of Medicine. 
Results 
Characteristics of study cohort 
1,100 blood samples and thick smears were collected 
from 555 children aged 1-17 years (mean age 9.68 ± 
0.18) in the Amele region, Madang Province, P N G at two 
surveys in November-December of 1999 and 2000. 
Thirty-eight percent of samples were slide-positive for P. 
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falciparum in both years of the study and 24.7% were 
positive for Plasmodium vivax. Only 57 samples (5.2%) 
were positive for both P. falciparum and P. vivax. Geomet-
ric mean parasite density of P. falciparum was 680 para-
sites/ul (95% CI 567-814) and parasite density was 
negatively correlated with age (/? = -0.08, standard error 
[SE] 0.02, P=.002). 
Table 1 details the frequency of polymorphisms investi-
gated in this study. High frequencies of a+-thalassaemia 
were found in this population (92.9%) with a predomi-
nance of the 4.2 deletion allele (frequency = 0.71). The 
CR1 L allele was also predominant with a prevalence of 
94.6%, whereas the host erythrocyte polymorphisms SAO 
and G6PD were relatively uncommon in this population 
(< 10%). 
Host polymorphisms and P. falciparum prevalence and 
density 
Table 1 also details whether a child was P. falciparum pos-
itive for one survey, two surveys or no surveys, according 
to host polymorphism. There was no association of a+-
thalassaemia (P > .7), SAO (P = .29) or G6PD deficiency 
(P > .3) with P. falciparum prevalence either at both 
surveys, after adjustments for age. There was also no 
significant association of a+-thalassaemia (P = .78), SAO 
(P = .66) or G6PD deficiency (P = .64) with mean parasite 
density, after adjustments for age. Children who were 
blood group B were less likely to be positive at both sur-
veys compared to those who were blood group O (P = 
.005). When P. falciparum prevalence was analysed sepa-
rately for each year, blood group B had a significantly 
lower prevalence of P. falciparum (27.8%) compared to O 
(43.3%) in 2000 only (P = .02). There was no significant 
difference in mean parasite densities between ABO blood 
groups (P < .4) as assessed by a mixed linear model, with 
adjustments for age. Children with the CR1 HL genotype 
were more likely to be P. falciparum positive for both sur-
veys compared to H H individuals but this was of border-
line significance (P = .07). There was also weak evidence 
of CR1 H H genotype having lower geometric mean para-
site densities (322 P. falciparum/ul, 95%CI 129-807) 
compared to those who were HL (786 P. falciparum/ul, 
95% CI 584-1058, P = .07) or LL genotype (688 P. falci-
parum/^, 95% CI 540-876, P = .12). 
Host polymorphisms and age-specific seroconversion to 
VSA 
A multivariate linear mixed model was used to examine 
the effect of age and parasitaemia on antibody levels 
Table 1: Host polymorphism and parasitological data for 555 children from the Amele region, Papua New Guinea 
Host Polymorphism 
<x+-Thalassaemia 
(aa /aa) 
(-a/aa) 
(-a/-a) 
CR1 C 
HH 
HL 
LL 
A B O 
O 
non-O 
A 
B 
AB 
S A O 
Normal 
SAO 
G6PD C 
Normal 
Intermediate 
Deficient 
Frequency 
n (%) 
39(7.1) 
205 (36.9) 
311(56.0) 
29 (5.4) 
188(35.5) 
313 (59.1) 
180(32.6) 
372 (67.4) 
178(32.2) 
138(25.0) 
56(10.1) 
506 (91.2) 
49 (8.8) 
477 (89.7) 
20 (3.8) 
35 (6.6) 
Negative 
Both surveys 
n (%) 
15 (38.5) 
75 (37.1) 
125 (41.7) 
14 (48.3) 
70 (38.0) 
121 (39.9) 
69 (39.4) 
145 (39.9) 
62 (35.6) 
62 (46.6) 
21 (37.5) 
200 (40.4) 
15 (32.6) 
182 (39.1) 
8 (44.4) 
16(45.7) 
P. falciparum Prevalence3 
Positive 
One survey 
n (%) 
19(48.7) 
94 (46.5) 
120(40.0) 
12(41.4) 
78 (42.4) 
133 (43.9) 
66 (37.7) 
165 (45.5) 
80 (46.0) 
58 (43.6) 
27 (48.2) 
211 (42.6) 
22 (47.8) 
199(42.7) 
6 (33.3) 
16(45.7) 
Positive 
Both surveys 
n(%) 
5(12.8) 
33 (16.3) 
55 (18.3) 
3 (10.3) 
36 (19.6) 
49(16.2) 
40 (22.9) 
53 (14.6) 
32 (18.4) 
13 (9.8) 
8 (14.3) 
84 (17.0) 
9(19.6) 
85 (18.2) 
4 (22.2) 
3 (8.6) 
p, 
0.72 
0.99 
0.07 
0.11 
0.09 
0.83 
0.005 
0.27 
0.29 
0.76 
0.36 
* Missing data: 1999, n = 1; 2000, n = 21. 
b
 Differences in frequency of positive slides were assessed using ordinal regression with adjustments for age. 
c
 Abbreviations: C R 1 , Complement receptor 1; S A O , Southeast Asian Ovalocytosis; G6PD, Glucose-6-phosphate dehydrogenase deficiency. Wi th 
the exception of S A O , these variables contain missing values. 
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in samples from the cohort. Both age (J3 = 0.16, SE 0.009, 
P< .001) and parasitaemia (/?= 0.03, SE 0.007, P < .001) 
were found to positively influence antibody levels. This 
model was then applied to each of the five host erythro-
cyte polymorphisms investigated in this study. There was 
no significant difference in the age-dependent acquisition 
of VSA-specific antibodies with respect to ABO blood 
groups (P > .39), SAO (P = .39), or CR1 genotype (P = 
.99). There was also no significant difference in age-
dependent seroconversion in children with G6PD 
deficiency (P > .2), nor was there evidence of an interac-
tion between G6PD deficiency and sex (P = .16). There 
was an effect of a+-thalassaemia on age-dependent anti-
VSA antibody acquisition (Figure 1). Children who were 
heterozygous for a+-thalassaemia had a slower rate of 
antibody acquisition compared to children of normal 
genotype (P = .02). There was no significant difference in 
rate of antibody acquisition between children of normal 
genotype and those that were homozygous for a+-thalas-
saemia (P = .14). 
Discussion 
This study investigated age-specific antibody seroconver-
sion in Amele villages on the north coast of PNG, where 
malaria transmission is intense [70]. The sample size of 
the study was sufficiently large to allow us to look for 
interactions among the most common polymorphisms. 
Age (years) 
Figure 1 
Age-specific seroconversion to P. falciparum-infected 
erythrocyte variant surface antigens according to a+-
thalassaemia genotype. Antibody levels are expressed as 
the percentage relative response to a hyper-immune plasma 
control (HIP). Data represent the predicted antibody levels 
from a mixed linear model including age, P. falciparum parasi-
taemia (with parasitaemia set to 0) and a+-thalassaemia geno-
type. There was statistical significance between children of 
normal genotype and children heterozygous for a+-thalassae-
mia only (P = 0.02). 
Age was positively correlated with seroconversion to VSA, 
reflecting the association of age with exposure to malaria 
[66]. Parasitaemia was also positively correlated with VSA 
antibody levels. This result is similar to what has previ-
ously been shown in asymptomatic African populations 
to heterologous VSA [79]. It is therefore essential to make 
appropriate adjustments for age and parasitaemia when 
examining the association of host erythrocyte polymor-
phisms with age-specific antibody seroconversion. 
Papua New Guinean children who are homozygous, but 
not heterozygous, for a+-thalassaemia are protected 
against severe malaria [1]. These children have signifi-
cantly smaller erythrocytes compared to children of nor-
mal genotype, whereas erythrocyte parameters in 
heterozygotes are indistinguishable from normal individ-
uals [80]. If there is a reduced physical interaction 
(i.e reduced invasion/growth, rosetting) or enhanced 
immune-mediated response between microcytic erythro-
cytes and P. falciparum, then a difference in parasite prev-
alence/density and seroconversion would be expected 
between homozygous children and those of normal gen-
otype. This study showed there was no significant differ-
ence in age-specific seroconversion among these 
genotypes. Furthermore, there was no significant differ-
ence in P. falciparum density between a+-thalassaemia 
genotypes which is in concordance with other studies in 
children with asymptomatic parasitaemia [4,11,60-62]. 
There was some evidence of children of normal genotype 
having increased exposure compared to children who 
were heterozygous, but not homozygous, for a+-thalassae-
mia. This was surprising given that erythrocyte indices for 
heterozygotes are similar to children of normal genotype 
[80]. There is strong evidence that a+-thalassaemia confers 
particular protection against severe malarial anaemia. 
This must be independent of parasite density which has 
shown to be similar among a+-thalassaemia genotypes in 
children with acute malaria [1-4]. 
CR1 deficiency and blood group O are thought to protect 
against malaria by decreased rosetting. A positive correla-
tion has been shown between rosetting and P. falciparum 
parasitaemia and it has been proposed that rosetting may 
enhance parasite survival by facilitating invasion and pro-
moting immune evasion [81]. Polymorphisms associated 
with increased rosetting such as the CR1 H allele and AB 
blood antigens should lead to increased parasitaemia by 
this proposed mechanism. Contrary to this expectation, 
this study showed weak evidence of children with high 
levels of CR1 expression (HH) having lower P. falciparum 
prevalence and densities compared to children with lower 
CR1 expression (HL or LL genotype). This result could 
have occurred by chance given that only 15 children 
with H H were P. falciparum positive during the study. 
There was also evidence of blood group B having lower P. 
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falciparum prevalence in the 2000 survey, but there was no 
significant difference in parasite densities among ABO 
blood groups. Neither ABO blood group and C R l geno-
type had no effect on age-dependent seroconversion to 
anti-VSA antibodies, indicating that differences in parasi-
tological data in these groups must have been due to 
chance. This study would support the hypothesis that 
ABO blood group and C R l deficiency associated with the 
L allele protect against malaria by reduced rosetting and 
associated pathology rather than parasite density. 
There was no significant difference in geometric mean 
parasite densities or rates of seroconversion to P. falci-
parum VSA with respect to G6PD and SAO genotypes. 
These data conflict with several studies that have pro-
posed that innate resistance to malaria involved the ina-
bility for the malaria parasite to grow in and/or invade 
G6PD deficient and SAO erythrocytes [23]. There was also 
no evidence of an interaction between G6PD deficiency 
and sex with respect to anti-VSA seroconversion. A recent 
case-control study demonstrated that males, but not 
females, with G6PD deficiency were protected against 
severe malaria [12], but there was no significant difference 
in parasite density. Results presented here concur with this 
latter observation. 
Conclusion 
Data presented here highlight the importance of measur-
ing malaria exposure at two time points to investigate the 
interactions of host polymorphisms with the malaria par-
asite. Results can occur by chance, and previous studies 
have reported data from a single time point. No polymor-
phism showed both a reduction in parasite prevalence/ 
density and age-specific seroconversion to anti-VSA anti-
bodies. We interpret these findings to indicate that the 
mechanisms of protection by these polymorphisms are 
not fully explained by either structural aspects of the 
erythrocyte preventing infection or by enhanced immune 
responses to VSA. Our observations from P N G differ sig-
nificantly from those we and others have seen for African 
children with HbAS and/or Hb C carriers. HbAS individu-
als have lower parasite prevalence/densities and delayed 
time to reinfection, as well as increased prevalence of anti-
VSA antibodies, compared to those of normal genotype 
[18,24,36-39,44,82,83]. Whereas HbC carriers exhibit no 
differences in parasite density, yet higher immune 
responses to VSA [83]. The enhanced immune reactivity in 
Hb S and HbC carriers would suggest that protection 
against malaria is partially mediated by acquired immu-
nity. Conversely, the polymorphisms investigated in P N G 
may confer protection against the clinical pathologies of 
P. falciparum infection by a mechanism that does not 
influence parasite density or immunity to VSA. 
Authors' contributions 
FJIF performed data analysis, interpreted data and pre-
pared the final manuscript with KPD. P M helped to draft 
the manuscript and undertook laboratory work (FACS 
assay and PCR-based host genotyping except C R l ) . LP 
and C M W helped undertake laboratory work and inter-
pret data. HI and LT undertook laboratory and field work. 
RR participated in the design of analysis. CSM, AJFL and 
KPD conceived the study, participated in its design, and 
obtained funding for the project. All authors discussed the 
results and approved the final manuscript. 
Acknowledgements 
W e thank all the Amele volunteers for their participation in the study and 
the staff from the Papua New Guinea Institute of Medical Research in 
Madang for their assistance in collecting and processing blood samples and 
for malaria microscopy readings. This investigation received financial sup-
port from the Wellcome Trust (Programme grant N o 041354) and the 
European Union I N C O Programme (contract no. IC18-CT98-0359). The 
authors have no conflicts of interest. 
References 
1. Allen SJ, O'Donnell A, Alexander N D , Alpers MP, Peto TE, Clegg JB, 
Weatherall DJ: alpha+-Thalassemia protects children against 
disease caused by other infections as well as malaria. Proc Natl 
Acad Sci USA 1997, 94:14736-14741. 
2. Mockenhaupt FP, Ehrhardt S, Gellert S, Otchwemah R N , Dietz E, 
Anemana SD, Bienzle U: alpha+-Thalassemia protects African 
children from severe malaria. Blood 2004, 104:2003-2006. 
3. Williams T N , Wambua S, Uyoga S, Macharia A, Mwacharo JK, New-
ton CR, Maitland K: Both heterozygous and homozygous 
alpha+ thalassemias protect against severe and fatal Plasmo-
dium falciparum malaria on the coast of Kenya. Blood 2005, 
106:368-371. 
4. Wambua S, Mwangi T W , Kortok M, Uyoga SM, Macharia A W , Mwa-
charo JK, Weatherall DJ, Snow R W , Marsh K, Williams T N : The 
effect of alpha(+)-thalassaemia on the incidence of malaria 
and other diseases in children living on the coast of Kenya. 
P/_oS Med 2006, 3:e158. 
5. Cockburn IA, Mackinnon MJ, O'Donnell A, Allen SJ, Moulds JM, Baisor 
M, Bockarie M, Reeder JC, Rowe JA: A human complement 
receptor 1 polymorphism that reduces Plasmodium falci-
parum rosetting confers protection against severe malaria. 
Proc Natl Acad Sci USA 2004, 101:272-277. 
6. Ruwende C, Khoo SC, Snow R W , Yates SN, Kwiatkowski D, Gupta 
S, Warn P, Allsopp CE, Gilbert SC, Peschu N, Newbold CI, Green-
wood BM, Marsh K, Hill AVS: Natural selection of hemi- and het-
erozygotes for G6PD deficiency in Africa by resistance to 
severe malaria. Nature 1995, 376:246-249. 
7. Allen SJ, O'Donnell A, Alexander N D , Mgone CS, Peto TE, Clegg JB, 
Alpers MP, Weatherall DJ: Prevention of cerebral malaria in 
children in Papua New Guinea by southeast Asian ovalocyto-
sis band 3. Am 1 Trop Med Hyg 1999, 60:1056-1060. 
8. Genton B, al-Yaman F, Mgone CS, Alexander N, Paniu M M , Alpers 
MP, Mokela D: Ovalocytosis and cerebral malaria [letter]. 
Nature 1995, 378:564-565. 
9. Fischer PR, Boone P: Short report: severe malaria associated 
with blood group. Am 1 Trop Med Hyg 1998, 58:122-123. 
10. Lell B, May J, Schmidt-Ott RJ, Lehman LG, Luckner D, Greve B, 
Matousek P, Schmid D, Herbich K, Mockenhaupt FP, Meyer C G , Bien-
zle U, Kremsner PG: The role of red blood cell polymorphisms 
in resistance and susceptibility to malaria. Clin Infect Dis 1999, 
28:794-799. 
11. Williams T N , Mwangi T W , Wambua S, Peto TE, Weatherall DJ, 
Gupta S, Recker M, Penman BS, Uyoga S, Macharia A, Mwacharo JK, 
Snow R W , Marsh K: Negative epistasis between the malaria-
protective effects of alpha(+)-thalassemia and the sickle cell 
trait. Nat Genet 2005, 37:1253-1257. 
Page 6 of 8 
(page number not for citation purposes) 
Malaria Journal 2008, 7:1 http://vwvw.malariajournal.eom/content/7/1/1 
12. Guindo A, Fairhurst RM, Doumbo OK , Wellems TE, Diallo DA: X -
Linked G6PD deficiency protects hemizygous males but not 
heterozygous females against severe malaria. PLoS Med 2007, 
4:e66. 
13. Agarwal A, Guindo A, Cissoko Y, Taylor JG, Coulibaly D, Kone A, 
Kayentao K, Djimde A, Plowe CV, Doumbo O, Wellems TE, Diallo 
D: Hemoglobin C associated with protection from severe 
malaria in the Dogon of Mali, a West African population with 
a low prevalence of hemoglobin S. Blood 2000, 96:2358-2363. 
14. Mockenhaupt FP, Ehrhardt S, Cramer JP, Otchwemah R N , Anemana 
SD, Goltz K, Mylius F, Dietz E, Eggelte TA, Bienzle U: Hemoglobin 
C and resistance to severe malaria in Ghanaian children. 1 
Infect Dis 2004, 190:1006-1009. 
15. Modiano D, Luoni G, Sirima BS, Simpore J, Verra F, Konate A, Rast-
relli E, Olivieri A, Calissano C, Paganotti G M , D'Urbano L, Sanou I, 
Sawadogo A, Modiano G, Coluzzi M: Haemoglobin C protects 
against clinical Plasmodium falciparum malaria. Nature 2001, 
414:305-308. 
16. Hutagalung R, Wilairatana P, Looareesuwan S, Brittenham G M , 
Aikawa M, Gordeuk VR: Influence of hemoglobin E trait on the 
severity of Falciparum malaria. 1 Infect Dis 1999, 179:283-286. 
17. Chotivanich K, Udomsangpetch R, Pattanapanyasat K, Chierakul W , 
Simpson J, Looareesuwan S, White N: Hemoglobin E: a balanced 
polymorphism protective against high parasitemias and thus 
severe P falciparum malaria. Blood 2002, 100:1172-1176. 
18. Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki 
S, Nahlen BL, Lai AA, Udhayakumar V: Protective effects of the 
sickle cell gene against malaria morbidity and mortality. Lan-
cet 2002, 359:1311-1312. 
19. Williams T N , Mwangi T W , Roberts DJ, Alexander N D , Weatherall 
DJ, Wambua S, Kortok M, Snow R W , Marsh K: A n Immune Basis 
for Malaria Protection by the Sickle Cell Trait. PLoS Med 2005, 
2:e128. 
20. Williams T N , Mwangi T W , Wambua S, Alexander N D , Kortok M, 
Snow R W , Marsh K: Sickle Cell Trait and the Risk of Plasmo-
dium falciparum Malaria and Other Childhood Diseases. 1 
Infect Dis 2005, 192:178-186. 
21. Rowe JA, Handel IG, Thera MA, Deans A M , Lyke KE, Kone A, Diallo 
DA, Raza A, Kai O, Marsh K, Plowe CV, Doumbo OK , Moulds JM: 
Blood group O protects against severe Plasmodium falci-
parum malaria through the mechanism of reduced rosetting. 
Proc Natl Acad Sci USA 2007, 104:17471-17476. 
22. May J, Evans JA, Timmann C, Ehmen C, Busch W , Thye T, Agbenyega 
T, Horstmann RD: Hemoglobin variants and disease manifes-
tations in severe falciparum malaria. 1AMA 2007, 
297:2220-2226. 
23. Williams T N : Red blood cell defects and malaria. Mol Biochem 
Parasitol 2006, 149:121-127. 
24. Ayi K, Turrini F, Piga A, Arese P: Enhanced phagocytosis of ring-
parasitized mutant erythrocytes. A common mechanism 
that may explain protection against falciparum-malaria in 
sickle-trait and beta-thalassemia-trait. Blood 2004, 
104:3364-3371. 
25. Giribaldi G, Ulliers D, Mannu F, Arese P, Turrini F: Growth of Plas-
modium falciparum induces stage-dependent haemichrome 
formation, oxidative aggregation of band 3, membrane dep-
osition of complement and antibodies, and phagocytosis of 
parasitized erythrocytes. Br ] Haematol 2001, 113:492-499. 
26. Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F, Ulliers D, 
Simula G, Luzzatto L, Arese P: Early phagocytosis of glucose-6-
phosphate dehydrogenase (G6PD)-deficient erythrocytes 
parasitized by Plasmodium falciparum may explain malaria 
protection in G6PD deficiency. Blood 1998, 92:2527-2534. 
27. Destro-Bisol G, D'Aloja E, Spedini G, Scatena R, Giardina B, Pascali V: 
Brief communication: Resistance to Falciparum malaria in 
alpha-thalassemia, oxidative stress, and hemoglobin oxida-
tion. Am IPhys /Whropo/1999, 109:269-273. 
28. Luzzi GA, Merry A H , Newbold CI, Marsh K, Pasvol G: Protection 
by alpha-thalassaemia against Plasmodium falciparum 
malaria: modified surface antigen expression rather than 
impaired growth or cytoadherence. Immunol Lett 1991, 
30:233-240. 
29. Stoute JA: Complement-regulatory proteins in severe 
malaria: too little or too much of a good thing? Trends Parasitol 
2005, 21:218-223. 
30. Rowe A, Obeiro J, Newbold CI, Marsh K: Plasmodium falciparum 
rosetting is associated with malaria severity in Kenya. Infect 
Immun 1995, 63:2323-2326. 
31. Udomsangpetch R, Todd J, Carlson J, Greenwood BM: The effects 
of hemoglobin genotype and A B O blood group on the for-
mation of rosettes by Plasmodium fa/c/parum-infected red 
blood cells. Am 1 Trop Med Hyg 1993, 48:149-153. 
32. Carlson J, Nash GB, Gabutti V, al-Yaman F, Wahlgren M: Natural 
protection against severe Plasmodium falciparum malaria due 
to impaired rosette formation. Stood 1994, 84:3909-3914. 
33. Allison A C : Protection afforded by sickle-cell trait against sub-
tertian malareal infection. Br Med 11954, 1(4857):290-4. 
34. Hill AV, Allsopp CE, Kwiatkowski D, Anstey N M , Twumasi P, Rowe 
PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM: C o m -
mon west African H L A antigens are associated with protec-
tion from severe malaria. Nature 1991, 352:595-600. 
35. Allen SJ, Rowe P, Allsopp CE, Riley EM, Jakobsen PH, Hill AV, Green-
wood BM: A prospective study of the influence of alpha tha-
lassaemia on morbidity from malaria and immune responses 
to defined Plasmodium falciparum antigens in Gambian chil-
dren. Trans R Soc Trop Med Hyg 1993, 87:282-285. 
36. Aluoch JR: Higher resistance to Plasmodium falciparum infec-
tion in patients with homozygous sickle cell disease in west-
ern Kenya. Trop Med Int Health 1997, 2:568-571. 
37. Le Hesran JY, Personne I, Personne P, Fievet N, Dubois B, Beyeme M, 
Boudin C, Cot M, Deloron P: Longitudinal study of Plasmodium 
falciparum infection and immune responses in infants with or 
without the sickle cell trait. Int 1 Epidemiol 1999, 28:793-798. 
38. Marsh K, Otoo L, Hayes RJ, Carson D C , Greenwood BM: Antibod-
ies to blood stage antigens of Plasmodium falciparum in rural 
Gambians and their relation to protection against infection. 
Trans R Soc Trop Med Hyg 1989, 83:293-303. 
39. Sokhna CS, Rogier C, Dieye A, Trape JF: Host factors affecting the 
delay of reappearance of Plasmodium falciparum after radical 
treatment among a semi-immune population exposed to 
intense perennial transmission. Am 1 Trop Med Hyg 2000, 
62:266-270. 
40. Ackerman H, Usen S, Jallow M, Sisay-Joof F, Pinder M, Kwiatkowski 
DP: A comparison of case-control and family-based associa-
tion methods: the example of sickle-cell and malaria. Ann 
Hum Genet 2005, 69:559-565. 
41. Missinou MA, LeII B, Kremsner PG: Uncommon asymptomatic 
Plasmodium falciparum infections in Gabonese children. Clin 
Infect Dis 2003, 36:1198-1202. 
42. Fleming AF, Storey J, Molineaux L, Iroko EA, Attai ED: Abnormal 
haemoglobins in the Sudan savanna of Nigeria. I. Prevalence 
of haemoglobins and relationships between sickle cell trait, 
malaria and survival. Ann Trop Med Parasitol 1979, 73:161-172. 
43. Gendrel D, Kombila M, Nardou M, Gendrel C, Djouba F, Richard-
Lenoble D: Protection against Plasmodium falciparum infec-
tion in children with hemoglobin S. Pediatr Infect Dis 1 1991, 
10:620-621. 
44. Allen SJ, Bennett S, Riley EM, Rowe PA, Jakobsen PH, O'Donnell A, 
Greenwood BM: Morbidity from malaria and immune 
responses to defined Plasmodium falciparum antigens in chil-
dren with sickle cell trait in The Gambia. Trans R Soc Trop Med 
Hyg 1992, 86:494-498. 
45. Oppenheimer SJ, Higgs DR, Weatherall DJ, Barker J, Spark RA: Alpha 
thalassaemia in Papua New Guinea. Lancet 1984, 1:424-426. 
46. Enevold A, Alifrangis M, Sanchez JJ, Carneiro I, Roper C, Borsting C, 
Lusingu J, Vestergaard LS, Lemnge M M , Morling N, riley E, Drakely CJ: 
Associations between alpha+-thalassemia and Plasmodium 
falciparum malarial infection in northeastern Tanzania. Jour-
nal of Infectious Diseases 2007, 196:451-459. 
47. Cattani JA, Gibson FD, Alpers MP, Crane G G : Hereditary ovalocy-
tosis and reduced susceptibility to malaria in Papua New 
Guinea. Trans R Soc Trop Med Hyg 1987, 81 (5):705-9. 
48. Foo LC, Rekhraj V, Chiang GL, Mak JW: Ovalocytosis protects 
against severe malaria parasitemia in the Malayan aborigi-
nes. Am ] Trop Med Hyg 1992, 47:271-275. 
49. Domarle O , Migot-Nabias F, Mvoukani JL, Lu CY , Nabias R, Mayombo 
J, Tiga H, Deloron P: Factors influencing resistance to reinfec-
tion with Plasmodium falciparum. Am 1 Trop Med Hyg 1999, 
61:926-931. 
50. Moyano M, Mendez F: [Erythrocyte defects and parasitemia 
density in patients with Plasmodium falciparum malaria in 
Page 7 of 8 
(page number not for citation purposes) 
Malaria Journal 2008, 7:1 http://vwvw.malariajournal.eom/content/7/1/1 
Buenaventura, Colombia]. Rev Panam Salud Publica 2005, 
18:25-32. 
51. Parikh S, Dorsey G, Rosenthal PJ: Host polymorphisms and the 
incidence of malaria in Ugandan children. Am 1 Trop Med Hyg 
2004, 71:750-753. 
52. Mombo LE, Ntoumi F, Bisseye C, Ossari S, Lu CY , Nagel RL, Krishna-
moorthy R: Human genetic polymorphisms and asympto-
matic Plasmodium falciparum malaria in Gabonese 
schoolchildren. Am 1 Trop Med Hyg 2003, 68:186-190. 
53. O o M, Tin S, Marlar T, O'Sullivan WJ: Genetic red cell disorders 
and severity of falciparum malaria in Myanmar. Bull World 
Health Organ 1995, 73:659-665. 
54. Imrie H, Fowkes FJ, Michon P, Tavul L, Hume JC, Piper KP, Reeder JC, 
Day KP: Haptoglobin levels are associated with haptoglobin 
genotype and {alpha}+-thalassemia in a malaria-endemic 
area. Am 1 Trop Med Hyg 2006, 74:965-971. 
55. Montoya F, Restrepo M, Montoya AE, Rojas W : Blood groups and 
malaria. Rev Inst Med Trop Sao Paulo 1994, 36:33-38. 
56. Shimizu H, Tamam M, Soemantri A, Ishida T: Glucose-6-phosphate 
dehydrogenase deficiency and Southeast Asian ovalocytosis 
in asymptomatic Plasmodium carriers in Sumba island, 
Indonesia. ] Hum Genet 2005, 50:420-424. 
57. Patel SS, King CL, Mgone CS, Kazura JW, Zimmerman PA: Glycoph-
orin C (Gerbich antigen blood group) and band 3 polymor-
phisms in two malaria holoendemic regions of Papua New 
Guinea. Am 1 Hematol 2004, 75:1-5. 
58. Facer CA , Brown J: A B O blood groups and falciparum malaria. 
Trans R Soc Trop Med Hyg 1979, 73:599-600. 
59. Martin SK, Miller LH, Hicks C U , David-West A, Ugbode C, Deane M: 
Frequency of blood group antigens in Nigerian children with 
falciparum malaria. Trans R Soc Trop Med Hyg 1979, 73:216-218. 
60. Mockenhaupt FP, Falusi A G , May J, Ademowo O G , Olumese PE, 
Meyer C G , Bienzle U: The contribution of alpha+-thalassaemia 
to anaemia in a Nigerian population exposed to intense 
malaria transmission. Trop Med Int Health 1999, 4:302-307. 
61. Oppenheimer SJ, Hill AV, Gibson FD, Macfarlane SB, Moody JB, Prin-
gle J: The interaction of alpha thalassaemia with malaria. 
Trans R Soc Trop Med Hyg 1987, 81:322-326. 
62. Williams T N , Maitland K, Bennett S, Ganczakowski M, Peto TE, New-
bold CI, Bowden DK, Weatherall DJ, Clegg JB: High incidence of 
malaria in alpha-thalassaemic children. Nature 1996, 
383:522-525. 
63. Bienzle U, Guggenmoos-Holzmann I, Luzzatto L: Plasmodium falci-
parum malaria and human red cells. I. A genetic and clinical 
study in children. Int 1 Epidemiol 1981, 10:9-15. 
64. O'Donnell A, Allen SJ, Mgone CS, Martinson JJ, Clegg JB, Weatherall 
DJ: Red cell morphology and malaria anaemia in children 
with Southeast-Asian ovalocytosis band 3 in Papua New 
Guinea. Br 1 Haematol 1998, 101:407-412. 
65. Fowkes FJ, Imrie H, Migot-Nabias F, Michon P, Justice A, Deloron P, 
Luty AJ, Day KP: Association of haptoglobin levels with age, 
parasite density, and haptoglobin genotype in a malaria-
endemic area of Gabon. Am 1 Trop Med Hyg 2006, 74:26-30. 
66. Snow R W , Marsh K: New insights into the epidemiology of 
malaria relevant for disease control. Br Med Bull 1998, 
54:293-309. 
67. Piper KP, Roberts DJ, Day KP: Plasmodium falciparum: analysis of 
the antibody specificity to the surface of the trophozoite-
infected erythrocyte. Exp Parasitol 1999, 91:161-169. 
68. Askjaer N, Maxwell C, Chambo W , Staalsoe T, Nielsen M, Hviid L, 
Curtis C, Theander TG: Insecticide-treated bed nets reduce 
plasma antibody levels and limit the repertoire of antibodies 
to Plasmodium falciparum variant surface antigens. Clin Diagn 
Lab Immunol 2001, 8:1289-1291. 
69. Gupta S, Trenholme K, Anderson RM, Day KP: Antigenic diversity 
and the transmission dynamics of Plasmodium falciparum. Sci-
ence 1994, 263:961-963. 
70. Cattani JA, Tulloch JL, Vrbova H, Jolley D, Gibson FD, Moir JS, Hey-
wood PF, Alpers MP, Stevenson A, Clancy R: The epidemiology of 
malaria in a population surrounding Madang, Papua New 
Guinea. Am 1 Trop Med Hyg 1986, 35:3-15. 
71. Jarolim P, PalekJ, Amato D, Hassan K, Sapak P, Nurse GT, Rubin HL, 
Zhai S, Sahr KE, Liu SC: Deletion in erythrocyte band 3 gene in 
malaria-resistant Southeast Asian ovalocytosis. Proc Natl Acad 
Sci USA 1991, 88:11022-11026. 
72. Zhang L, Cui X , Schmitt K, Hubert R, Navidi W , Arnheim N: Whole 
genome amplification from a single cell: implications for 
genetic analysis. Proc Natl Acad Sci USA 1992, 89:5847-5851. 
73. Cox MJ, Kum DE, Tavul L, Narara A, Raiko A, Baisor M, Alpers MP, 
Medley GF, Day KP: Dynamics of malaria parasitaemia associ-
ated with febrile illness in children from a rural area of 
Madang, Papua New Guinea. Trans R Soc Trop Med Hyg 1994, 
88:191-197. 
74. Trager W , Jensen JB: Human malaria parasites in continuous 
culture. Science 1976, 193:673-675. 
75. Day KP, Karamalis F, Thompson J, Barnes DA, Peterson C, Brown H, 
Brown GV, Kemp DJ: Genes necessary for expression of a viru-
lence determinant and for transmission of Plasmodium falci-
parum are located on a 0.3-megabase region of chromosome 
9. Proc Natl Acad Sci USA 1993, 90:8292-8296. 
76. Pasvol G, Wilson RJ, Smalley ME, Brown J: Separation of viable 
schizont-infected red cells of Plasmodium falciparum from 
human blood. Ann Trop Med Parasitol 1978, 72:87-88. 
77. Vulliamy T, Luzzatto L, Hirono A, Beutler E: Hematologically 
important mutations: glucose-6-phosphate dehydrogenase. 
Blood Cells Mol Dis 1997, 23:302-313. 
78. R Development Core Team: R: A Language and Environment 
for Statistical Computing. Vienna, Austria: R Foundation for Sta-
tistical Computing; 2005. 
79. Kinyanjui SM, Mwangi T, Bull PC, Newbold CI, Marsh K: Protection 
against clinical malaria by heterologous immunoglobulin G 
antibodies against malaria-infected erythrocyte variant sur-
face antigens requires interaction with asymptomatic infec-
tions. ] Infect Dis 2004, 190:1527-1533. 
80. Weatherall DJ, Clegg JB: The Thalassaemia Syndromes. 4th edi-
tion. Oxford: Blackwell Science; 2001. 
81. Rowe JA, Obiero J, Marsh K, Raza A: Short report: Positive cor-
relation between rosetting and parasitemia in Plasmodium 
falciparum clinical isolates. Am ] Trop Med Hyg 2002, 66:458-460. 
82. Cabrera G, Cot M, Migot-Nabias F, Kremsner PG, Deloron P, Luty 
AJ: The sickle cell trait is associated with enhanced immu-
noglobulin G antibody responses to Plasmodium falciparum 
variant surface antigens. 1 Infect Dis 2005, 191:1631 -1638. 
83. Verra F, Simpore J, Warimwe G M , Tetteh KK, Howard T, Osier FH, 
Bancone G, Avellino P, Blot I, Fegan G, et al:. Haemoglobin C and 
S Role in Acquired Immunity against Plasmodium falciparum 
Malaria. PLoS ONE 2007, 2:e978. 
Publish with Bio Med Central and every 
scientist can read your work free of charge 
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime." 
Sir Paul Nurse, Cancer Research UK 
Your research papers wi l l be: 
• available free of charge to the entire biomedical community 
• peer reviewed and published immediately upon acceptance 
• cited in PubMed and archived on PubMed Central 
• yours — you keep the copyright 
Submit your manuscript here: I J BioMedcentral 
http://www.biomedcentral.com/info/publishing_adv.asp ^ * — " 
Page 8 of 8 
(page number not for citation purposes) 
